Literature DB >> 25115301

Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells.

Assefa Wondimu1, Yihui Liu2, Yan Su1, Daniel Bobb1, Jennifer S Y Ma3, Lina Chakrabarti3, Saša Radoja4, Stephan Ladisch5.   

Abstract

Although it is now widely appreciated that antitumor immunity is critical to impede tumor growth and progression, there remain significant gaps in knowledge about the mechanisms used by tumors to escape immune control. In tumor cells, we hypothesized that one mechanism of immune escape used by tumors involves the synthesis and extracellular shedding of gangliosides, a class of biologically active cell surface glycosphingolipids with known immunosuppressive properties. In this study, we report that tumor cells engineered to be ganglioside deficient exhibit impaired tumorigenicity, supporting a link between ganglioside-dependent immune escape and tumor outgrowth. Notably, we documented a dramatic reduction in the numbers and function of tumor-infiltrating myeloid-derived suppressor cells (MDSC) in ganglioside-deficient tumors, in contrast with the large MDSC infiltrates seen in ganglioside-rich littermate control tumors. Transient ganglioside reconstitution of the tumor cell inoculum was sufficient to increase MDSC infiltration, supporting a direct connection between ganglioside production by tumor cells and the recruitment of immunosuppressive MDSC into the tumor microenvironment. Our results reveal a novel mechanism of immune escape that supports tumor growth, with broad implications given that many human tumors produce and shed high levels of gangliosides. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115301      PMCID: PMC4184983          DOI: 10.1158/0008-5472.CAN-14-0927

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells.

Authors:  G Alessandri; S Filippeschi; P Sinibaldi; F Mornet; P Passera; F Spreafico; P M Cappa; P M Gullino
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

2.  Shed tumor gangliosides and progression of human neuroblastoma.

Authors:  L Valentino; T Moss; E Olson; H J Wang; R Elashoff; S Ladisch
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

3.  Gangliosides influence angiogenesis in an experimental mouse brain tumor.

Authors:  M G Manfredi; S Lim; K P Claffey; T N Seyfried
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.

Authors:  G V Shurin; M R Shurin; S Bykovskaia; J Shogan; M T Lotze; E M Barksdale
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

5.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

Authors:  Li Yang; Laura M DeBusk; Koari Fukuda; Barbara Fingleton; Brenda Green-Jarvis; Yu Shyr; Lynn M Matrisian; David P Carbone; P Charles Lin
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

6.  Gangliosides shed by tumor cells enhance tumor formation in mice.

Authors:  S Ladisch; S Kitada; E F Hays
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

7.  Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides.

Authors:  S Ladisch; B Gillard; C Wong; L Ulsh
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

8.  Tumor gangliosides accelerate murine tumor angiogenesis.

Authors:  Yihui Liu; Assefa Wondimu; Su Yan; Daniel Bobb; Stephan Ladisch
Journal:  Angiogenesis       Date:  2013-10-29       Impact factor: 9.596

9.  Mechanisms of ganglioside inhibition of APC function.

Authors:  Sheila Caldwell; Andreas Heitger; Weiping Shen; Yihui Liu; Barbara Taylor; Stephan Ladisch
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

10.  Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase.

Authors:  Michael Weiss; Simone Hettmer; Paul Smith; Stephan Ladisch
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

View more
  10 in total

Review 1.  Anti-GD2 immunotherapy for neuroblastoma.

Authors:  Sameer Sait; Shakeel Modak
Journal:  Expert Rev Anticancer Ther       Date:  2017-08-14       Impact factor: 4.512

Review 2.  Lipid glycosylation: a primer for histochemists and cell biologists.

Authors:  Jürgen Kopitz
Journal:  Histochem Cell Biol       Date:  2016-12-20       Impact factor: 4.304

3.  Chemoenzymatic synthesis of the oligosaccharide moiety of the tumor-associated antigen disialosyl globopentaosylceramide.

Authors:  Ingrid M E 't Hart; Tiehai Li; Margreet A Wolfert; Shuo Wang; Kelley W Moremen; Geert-Jan Boons
Journal:  Org Biomol Chem       Date:  2019-08-07       Impact factor: 3.876

Review 4.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

5.  Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis.

Authors:  Richard Jennemann; Giuseppina Federico; Daniel Mathow; Mariona Rabionet; Francesca Rampoldi; Zoran V Popovic; Martina Volz; Thomas Hielscher; Roger Sandhoff; Hermann-Josef Gröne
Journal:  Oncotarget       Date:  2017-11-24

6.  The function of cancer-shed gangliosides in macrophage phenotype: involvement with angiogenesis.

Authors:  Tae-Wook Chung; Hee-Jung Choi; Mi-Ju Park; Hee-Jin Choi; Syng-Ook Lee; Keuk-Jun Kim; Cheorl-Ho Kim; Changwan Hong; Kyun-Ha Kim; Myungsoo Joo; Ki-Tae Ha
Journal:  Oncotarget       Date:  2017-01-17

Review 7.  Targets and Antibody Formats for Immunotherapy of Neuroblastoma.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

Review 8.  Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.

Authors:  Margarita Bartish; Sonia V Del Rincón; Christopher E Rudd; H Uri Saragovi
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

Review 9.  Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents.

Authors:  Jose Luis Daniotti; Ricardo D Lardone; Aldo A Vilcaes
Journal:  Front Oncol       Date:  2016-01-07       Impact factor: 6.244

Review 10.  Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.

Authors:  Claudia Rossig; Sareetha Kailayangiri; Silke Jamitzky; Bianca Altvater
Journal:  Front Oncol       Date:  2018-11-12       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.